Ado-Trastuzumab Emtansine
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 993 publications
Epitope selection for combination therapy using antibody-drug conjugates and immune immune-stimulating antibody conjugates.
Journal: Frontiers in immunology
Published: August 06, 2026
Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review.
Journal: Medicina (Kaunas, Lithuania)
Published: July 30, 2026
Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.
Journal: Breast cancer research and treatment
Published: July 10, 2026
Safety of concurrent T-DM1 and radiation therapy in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.
Journal: International journal of radiation biology
Published: June 04, 2026
Trastuzumab Emtansine-Associated Porto-Sinusoidal Vascular Disorder: Clinical Features and Outcomes from Published Cases.
Journal: Journal of clinical medicine
Published: April 28, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 24, 2026
Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support.
Journal: Frontiers in oncology
Published: April 18, 2026
Adverse Event Profiling and Comparative Analysis of HER2-targeting Antibody-drug Conjugates Using Pharmacovigilance Databases.
Journal: In vivo (Athens, Greece)
Published: April 06, 2026
Last Updated: 11/08/2026